JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dortch-Carnes, J.
Right arrow Articles by Potter, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dortch-Carnes, J.
Right arrow Articles by Potter, D. E.

Vol. 301, Issue 2, 599-604, May 2002

Inhibition of cAMP Accumulation by kappa -Receptor Activation in Isolated Iris-Ciliary Bodies: Role of Phosphodiesterase and Protein Kinase C

Juanita Dortch-Carnes and David E. Potter

Department of Pharmacology/Toxicology, Morehouse School of Medicine, Atlanta, Georgia

The present study was designed to examine the roles of protein kinase C (PKC) and phosphodiesterase (PDE) in modulating the action of kappa  receptor stimulation on cAMP accumulation in isolated iris-ciliary bodies (ICBs) of New Zealand White rabbits. The kappa  receptor agonist, (±)-1-(3,4-dichlorophenyl)acetyl-2-(1-pyrrolidinyl)methylpiperidine (BRL-52537) (BRL), and the PKC activator, phorbol 12,13-dibutyrate (PDBu), both caused a concentration-dependent inhibition of forskolin-stimulated cAMP production. The inhibitory effect of BRL on cAMP levels was significantly reduced in the presence of the selective kappa  receptor antagonist, norbinaltorphimine (10-6 M), but the effect of PDBu was not, thus supporting the involvement of kappa -opioid receptors in the response to BRL. In the presence of 3-isobutyl-1-methylxanthine or rolipram (10-5 M), the inhibitory effect of BRL or PDBu (10-6 M) on cyclic AMP accumulation was abolished. In the presence of the selective PKC antagonist, chelerythrine (10-6 M), the inhibitory effect of PDBu or BRL (10-6 M) was significantly reduced. Direct measurement of PDE activity demonstrated the ability of BRL and PDBu (10-6 M) to augment the activity of these enzymes. Preincubation of ICBs with rolipram (10-5 M) or chelerythrine (10-6 M) caused significant reversal of both BRL- and PDBu-induced increases in PDE activity. These results indicate that stimulation of PKC and PDE4 activity is part of the complex mechanism whereby kappa -opioid receptor agonists reduce levels of cAMP in the rabbit ICB. This mechanism of action could contribute to the ability of kappa -opioid agonists to suppress aqueous flow rate and to lower intraocular pressure.


0022-3565/02/3012-0599$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Neurosci.Home page
J. P. Britt and D. S. McGehee
Presynaptic Opioid and Nicotinic Receptor Modulation of Dopamine Overflow in the Nucleus Accumbens
J. Neurosci., February 13, 2008; 28(7): 1672 - 1681.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. E. Potter, K. R. M. Russell, and M. Manhiani
Bremazocine Increases C-Type Natriuretic Peptide Levels in Aqueous Humor and Enhances Outflow Facility
J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 548 - 553.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.